diabetes – Medxy AI

Donor Diabetes Status Does Not Compromise DMEK Outcomes: 1-Year Results from the DEKS Randomized Clinical Trial

By MedXY 01/10/2026

The Diabetes Endothelial Keratoplasty Study (DEKS) confirms that donor diabetes status has no clinically significant impact on 1-year graft success rates or endothelial cell loss after Descemet membrane endothelial keratoplasty (DMEK), facilitating a broader cornea donor pool.

Diabetes & Endocrinology Nephrology news

Beyond eGFR and UACR: kidneyintelX.dkd Refines Risk Stratification and Monitors Treatment Response in Diabetic Kidney Disease

By MedXY 12/31/2025

A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kidney disease.

Diabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

By MedXY 12/29/2025

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.

Cardiology Diabetes & Endocrinology news

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

By MedXY 12/24/2025

A prospective ARIC cohort study reveals that diabetes fundamentally modifies the relationship between the triglyceride-glucose (TyG) index and subclinical myocardial injury, shifting the risk profile from an L-shaped to a J-shaped association over a six-year follow-up.

Cardiology Clinical Updates Diabetes & Endocrinology news

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 12/22/2025

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy's cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Diabetes & Endocrinology Neurology news

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

By MedXY 12/17/2025

Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.

Diabetes & Endocrinology news Public Health

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

By MedXY 12/13/2025

This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.

Diabetes & Endocrinology Internal Medicine news

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy

By MedXY 11/17/2025

A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.

Diabetes & Endocrinology Neurology news

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

By MedXY 11/04/2025

A pan‑European analysis (n=5,550) found diabetes was associated with lower odds of amyloid and p‑tau pathology in cognitively impaired patients, but with markers of neurodegeneration (total tau, medial temporal atrophy) in cognitively normal individuals without amyloid — suggesting non‑AD pathways link diabetes to cognitive decline.

Dermatology Diabetes & Endocrinology news

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

By MedXY 11/01/2025

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

AI Clinical Updates Diabetes & Endocrinology news

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

By MedXY 10/29/2025

This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults with prediabetes and overweight or obesity.

Cardiology Diabetes & Endocrinology news

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

By MedXY 10/19/2025

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes status.

Clinical Updates Diabetes & Endocrinology news

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY 09/26/2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Cardiology Diabetes & Endocrinology news Specialties

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 09/10/2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Diabetes & Endocrinology news Specialties

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

By MedXY 09/07/2025

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Impact of Maternal Trace Element Levels on Neonatal Growth Among Diabetic and Non-Diabetic Pregnancies

By MedXY 08/30/2025

A case–control study reveals that elevated copper levels in diabetic pregnant women negatively affect newborn weight and head circumference, while chromium correlates positively with birth length. Smoking exposure adversely impacts infants’ weight, underscoring maternal trace element status and lifestyle as key determinants of neonatal outcomes.

Cardiology Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition Neurology news Specialties

Recent Advances in Cinnamon and Its Extracts: Clinical Applications and Therapeutic Potentials Across Metabolic, Cardiovascular, Cognitive, and Infectious Diseases

By MedXY 08/24/2025

A decade of research highlights cinnamon's benefits in glycemic control, lipid modulation, anti-inflammatory effects, cognitive enhancement, and antimicrobial activity, supporting its adjunctive clinical use and revealing promising therapeutic directions.

Cardiology Clinical Updates Diabetes & Endocrinology Specialties

Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial

By MedXY 08/24/2025

The PREVENT trial demonstrates that preventive PCI reduces adverse cardiac events in patients with vulnerable, non-flow-limiting coronary plaques, regardless of diabetes status, supporting a proactive interventional strategy alongside medical therapy.

Diabetes & Endocrinology Specialties

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

By MedXY 08/22/2025

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.

Diabetes & Endocrinology Specialties

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

By MedXY 08/22/2025

The ADA's 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.